Orasure Technologies (OSUR)
NASDAQ:OSUR
Want to see OSUR full AI Analyst Report?
Top Page
Orasure Technologies
(NASDAQ:OSUR)
Select Model
Select Model
Rating:54Neutral
Price Target:
$4.00
▲(68.07% Upside)
Action:Reiterated
Date:05/27/26
The score is held back primarily by sharply deteriorated financial performance (large losses, revenue decline, and negative free cash flow). Offsetting factors include an improving technical trend and a strong balance sheet with significant cash and no debt, while the earnings call and recent governance actions add moderate support but still carry meaningful execution risk.
Positive Factors
Conservative balance sheet
OraSure's large cash buffer and minimal leverage give it durable financial flexibility to fund product launches, near-shoring and working capital while losses persist. A strong balance sheet reduces refinancing risk, supports buybacks and preserves optionality to invest or transact as revenue recovers.
Negative Factors
Sharp revenue decline
A sustained ~26% revenue decline and the swing to deep net losses (~-62% net margin) reflect structural demand weakness or lost COVID-era volumes. This deterioration reduces operating leverage and makes return to durable profitability dependent on successful product ramps and market recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
OraSure's large cash buffer and minimal leverage give it durable financial flexibility to fund product launches, near-shoring and working capital while losses persist. A strong balance sheet reduces refinancing risk, supports buybacks and preserves optionality to invest or transact as revenue recovers.
Read all positive factors
Orasure Technologies (OSUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$291.23M
Dividend YieldN/A
Average Volume (3M)771.42K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue Growth-30.08%
EPS Growth-143.79%
CountryUS
Employees501
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-1.04
Shares Outstanding68,848,560
10 Day Avg. Volume735,713
30 Day Avg. Volume771,421
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit3.34
Enterprise Value/Ebitda-2.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$119.68M
Orasure Technologies Business Overview & Revenue Model
Company Description
OraSure Technologies, Inc. is a leader in the field of oral fluid diagnostics and medical devices, primarily focusing on the development and sale of products for the detection of infectious diseases and for drug testing. The company operates in tw...
How the Company Makes Money
OraSure makes money primarily by selling diagnostics and sample-collection products. Key revenue streams include: (1) Infectious disease diagnostics product sales: Revenue is generated from the sale of rapid and other diagnostic tests used to dete...
Orasure Technologies Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: positive execution on cost and manufacturing initiatives led to gross margin expansion and sequential diagnostics growth, a strong cash position and ongoing buybacks support financial flexibility, and two FDA-submitted products plus near-shoring progress are meaningful near- to mid-term growth catalysts. Offsetting these positives are substantial operating losses, negative operating cash flow, elevated near-term operating expenses (including nonrecurring charges), muted demand in some Sample Management end markets due to slow NIH funding, and execution/timing risks associated with product ramps and near-shoring monetization. Given the mix of encouraging operational progress and clear near-term financial and execution risks, the overall tone is balanced.Positive Updates
Revenue Above Guidance and Sequential Growth
Q1 total revenue of $27.9 million, which came in above the midpoint of guidance and grew 4% sequentially.
Negative Updates
Significant Operating Losses and Negative Operating Cash Flow
GAAP operating loss of $23.3 million and non-GAAP operating loss of $19.0 million in Q1. Operating cash flow was negative $14 million, with management projecting a return to breakeven operating cash flow only in 2027.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Above Guidance and Sequential Growth
Q1 total revenue of $27.9 million, which came in above the midpoint of guidance and grew 4% sequentially.
Read all positive updates
Company Guidance
For Q2 2026 OraSure guided revenue of $27.0–$30.0 million (with a negligible amount from COVID‑19 testing) and said Q2 gross margin should be similar to Q1 (Q1 GAAP gross margin 42.3%, non‑GAAP 43.4%), with operating expense in the high‑$20 million range (excluding stock compensation) and expected to decline to the mid‑$20 million range in Q3; R&D is expected to taper in Q2–Q3, G&A to normalize beginning in Q3, and management anticipates mid‑year FDA clearances with product revenue ramping in H2 2026 and a return to breakeven operating cash flow in 2027 (Q1 operating cash flow was negative $14.0M). For context, Q1 revenue was $27.9M (+4% sequential), Diagnostics $16.9M (+12% seq) and Sample Management $9.1M (flat), Q1 GAAP operating loss was $23.3M (non‑GAAP loss $19.0M), cash and cash equivalents were $177M with zero debt, and the company repurchased $5M (1.8M shares) in Q1 and $20M (7.1M shares) over the last four quarters.Orasure Technologies Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
74
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 113.02M | 115.02M | 185.83M | 405.47M | 387.48M | 233.67M |
| Gross Profit | 46.35M | 48.20M | 76.23M | 179.42M | 148.44M | 117.60M |
| EBITDA | -63.49M | -58.15M | -9.73M | 73.98M | 8.76M | 9.00K |
| Net Income | -75.07M | -68.73M | -19.50M | 53.66M | -17.13M | -23.00M |
Balance Sheet | ||||||
| Total Assets | 379.17M | 403.17M | 479.66M | 482.85M | 444.18M | 460.99M |
| Cash, Cash Equivalents and Short-Term Investments | 176.96M | 199.28M | 267.76M | 290.41M | 110.85M | 153.04M |
| Total Debt | 40.47M | 13.20M | 14.60M | 13.50M | 12.55M | 12.27M |
| Total Liabilities | 65.84M | 62.34M | 69.32M | 52.17M | 79.75M | 80.46M |
| Stockholders Equity | 313.32M | 340.83M | 410.34M | 430.67M | 364.43M | 380.53M |
Cash Flow | ||||||
| Free Cash Flow | -47.88M | -53.22K | 23.58M | 131.28M | -111.11M | -83.50M |
| Operating Cash Flow | -43.19M | -49.02K | 27.37M | 141.58M | -47.20M | -35.38M |
| Investing Cash Flow | -8.09M | -6.81K | -39.03M | 66.15M | 21.09M | -5.50M |
| Financing Cash Flow | -22.27M | -16.94K | -4.18M | -3.02M | -3.83M | -2.82M |
Orasure Technologies Technical Analysis
Positive
2.38
Price Trends
3.15
Positive
2.99
Positive
2.90
Positive
Market Momentum
0.27
Negative
85.03
Negative
92.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Positive. The current price of 2.38 is below the 20-day moving average (MA) of 3.28, below the 50-day MA of 3.15, and below the 200-day MA of 2.90, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 85.03 is Negative, neither overbought nor oversold. The STOCH value of 92.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSUR.
Orasure Technologies Risk Analysis
Orasure Technologies disclosed 66 risk factors in its most recent earnings report. Orasure Technologies reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Orasure Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $211.01M | 19.51 | 9.13% | 2.15% | -4.43% | -10.66% | |
60 Neutral | $182.85M | 23.17 | 14.00% | ― | 3.50% | 157.81% | |
55 Neutral | $218.01M | -5.91 | -246.44% | ― | 17.41% | -189.91% | |
54 Neutral | $291.23M | -3.99 | -21.50% | ― | -30.08% | -143.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $203.29M | -9.03 | -153.21% | ― | 13.40% | 20.97% |
* Healthcare Sector Average
OSUR
Orasure Technologies
4.30
1.42
49.31%
INFU
InfuSystem Holdings
9.07
3.29
56.92%
STXS
Stereotaxis
1.98
-0.15
-7.04%
UTMD
Utah Medical Products
66.45
12.50
23.17%
MBOT
Microbot Medical
2.03
-0.51
-20.08%
SMTI
Sanara MedTech
22.79
-6.21
-21.41%
Orasure Technologies Corporate Events
Business Operations and StrategyFinancial Disclosures
OraSure Technologies Reports First-Quarter 2026 Financial Results
Negative
May 6, 2026
On May 6, 2026, OraSure Technologies reported first-quarter 2026 results, posting total net revenues of $27.9 million, slightly below the prior year as COVID-19 and risk assessment testing revenues declined, but with core business sales essentiall...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
OraSure, Altai Capital Reach Governance Cooperation Agreement
Positive
Apr 17, 2026
On April 16, 2026, OraSure Technologies announced a cooperation agreement with activist investor Altai Capital, under which Altai withdrew prior director nominations and stockholder proposals and agreed to customary standstill and voting provision...
Business Operations and StrategyStock Buyback
OraSure Defends Strategy Amid Activist Altai Governance Challenge
Positive
Mar 30, 2026
On March 30, 2026, OraSure Technologies released a presentation defending its performance and governance in response to activist investor Altai Capital’s push to replace two independent directors, highlighting that its shareholder returns ha...
Executive/Board Changes
OraSure Technologies Announces Resignation of Board Member Shulkin
Neutral
Mar 5, 2026
On February 28, 2026, OraSure Technologies, Inc. announced that board member David J. Shulkin, M.D. had notified the company of his decision to resign as director and as a member of the Board’s Compensation Committee, effective March 2, 2026...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.